Compare Li Auto Inc (LI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs TG Therapeutics Inc — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Li Auto Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and TG Therapeutics Inc for 16 Days on average.
| LI | TGTX | |
|---|---|---|
Market Cap | $10.71B | $8.16B |
Volume | 1,781,143 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.13 | $59.06 |
52-Week Low | $10.69 | $26.94 |
Typical Hold Time | 101 Days | 16 Days |
Enterprise Value | $139.58M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows amid delivery moderation concerns. The stock shows bearish technical signals with negative moving averages and neutral oscillators. Fundamentally, revenue declined to $112.31B in 2025 with net income of $1.12B, though recent quarterly earnings missed expectations. Analyst sentiment is mixed with 44% buy ratings but a consensus price target of $15.18, suggesting 39% upside potential from current levels.
The outlook remains challenging with competitive pressures and cash flow concerns, but the company's strong balance sheet ($112.81B cash) provides cushion. New model launches (Li i9, MEGA) and global expansion could drive recovery, though execution risks and China's auto market weakness pose headwinds. The stock appears undervalued on P/S (0.73) and EV/EBITDA (1.72) metrics relative to growth potential.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
